Last updated: 2026-09-08 13:15:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
BillionToOne, Inc. (BLLN) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $99.25, with a market capitalization of $4.69B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $61.96 to $150.44. This page covers its latest market performance, valuation, price trends and company information.
$4.69B | |
$98.91 | |
$150.44 | |
$61.96 | |
-- | |
9.50K | |
734.41K | |
-- | |
$150.44 | |
$61.96 | |
-- | |
-- |
BillionToOne, Inc. (BLLN) is trading at $99.50 in pre-market trading as of 2026-09-08 12:47:00, -- from the previous close of $0.00
Pre-market trading shows how investors are pricing BLLN before the regular session opens. The current pre-market price is -- the previous close, indicating positive early trading sentiment.
Over the past seven days, BillionToOne, Inc. (BLLN) moved from $95.15 to $99.25, representing a gain of 4.31% ($4.10).
The stock traded between $89.78 and $102.48 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 571.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 42.1%
BLLN is currently trading at $99.25, placing it 42.1% of the way from its 52-week low of $61.96 to its 52-week high of $150.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 713 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BillionToOne, Inc. (BLLN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.